Addiction-Like Manifestations and Parkinson's Disease: A Large Single Center 9-Year Experience

REFERENCES

• Robinson TE, Berridge KC.Addiction. Annu Rev Psychol. 2003;54:25–53.
   PubMed Web of Science ®Google Scholar
• Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology. 2009;56 Suppl 1:18–31.
   PubMedGoogle Scholar
• Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–8.
   PubMed Web of Science ®Google Scholar
• Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1): 58–63.
   PubMedGoogle Scholar
• Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.
   PubMed Web of Science ®Google Scholar
• Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol. 2003;2(10):595–604.
   PubMed Web of Science ®Google Scholar
• DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281–5.
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31(1):89–98.
   PubMed Web of Science ®Google Scholar
• Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988;242(4879):715–23.
   PubMed Web of Science ®Google Scholar
• Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and “on-off” phenomena in Parkinson's disease. Mov Disord. 1990;5(2):148–51.
   PubMed Web of Science ®Google Scholar
• Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol. 2000;47(4 Suppl 1):S2–9; discussion S-11.
   PubMed Web of Science ®Google Scholar
• Goodwin FK. Psychiatric side effects of levodopa in man. JAMA. 1971;218(13):1915–20.
   PubMed Web of Science ®Google Scholar
• Bodi N, Keri S, Nagy H, Moustafa A, Myers CE, Daw N, Dibó G, Takáts A, Bereczki D, Gluck MA. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain. 2009;132(Pt 9):2385–95.
   PubMedGoogle Scholar
• Epping-Jordan MP, Watkins SS, Koob GF, Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature. 1998;393(6680):76–9.
   PubMed Web of Science ®Google Scholar
• Schulteis G, Markou A, Cole M, Koob GF. Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA. 1995;92(13):5880–4.
   PubMedGoogle Scholar
• Ahmed SH, Walker JR, Koob GF. Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology. 2000;22(4):413–21.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.
   PubMed Web of Science ®Google Scholar
• Fine J, Duff J, Chen R, Chir B, Hutchison W, Lozano AM, Lang AE. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. N Engl J Med. 2000;342(23):1708–14.
   PubMedGoogle Scholar
• Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?Neurology. 1999;52(6):1227–9.
   PubMed Web of Science ®Google Scholar
• Statistical manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, Lang AE, Miyasaki J. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66(11):1750–2.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE Jr, Pope HG Jr, Smith JM, Strakowski SM. Compulsive buying: a report of 20 cases. J Clin Psychiatry. 1994;55(6):242–8.
   PubMed Web of Science ®Google Scholar
• Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21(4):524–9.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord. 1999;14(5):836–8.
   PubMed Web of Science ®Google Scholar
• Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67(7):1254–7.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim JM, Kim JW, Cho J, Lee WY, Kim HJ, Jeon BS. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2009;16(3):202–7.
   PubMedGoogle Scholar
• Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS, Jeon BS. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord. 2009;24(12):1803–10.
   PubMed Web of Science ®Google Scholar
• Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, Stacy M. Impulse control disorders in Parkinson disease: A multicenter case-control study. Ann Neurol. 2011;69(6):986–96.
   PubMed Web of Science ®Google Scholar
• Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol. 2007;64(8):1089–96.
   PubMedGoogle Scholar
• Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 2005;65(10):1570–4.
   PubMed Web of Science ®Google Scholar
• Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67(7):1258–61.
   PubMedGoogle Scholar
• Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain. 2010;133(Pt 4):1111–27.
   PubMed Web of Science ®Google Scholar